Adjust Font Size:

Press Releases

Dr. Robert Lanza of Advanced Cell Technology Testifies Before Senate Subcommittee

Addresses Methods for Obtaining Embryonic Stem Cells and Strongly Urges Passage of the Stem Cell Research Enhancement Act of 2005

Worcester, MA, July 12, 2005 - Robert Lanza, M.D., Vice President of Medical and Scientific Development at Advanced Cell Technology, Inc. (OTCBB:ACTC.OB) testified today before the Senate Subcommittee on Labor, Health and Human Services, Education, and Related Agencies, of the Committee on Appropriations. Dr. Lanza's testimony focused on two approaches to creating pluripotent stem cell lines - that of single cell biopsy of embryos and the dedifferentiation of somatic cells back to pluripotency - and strongly encouraged support for the Stem Cell Research Enhancement Act of 2005.

"Given our research to date and animal models, further investigations should be funded and encouraged to determine if pluripotent stem cell lines can be derived in humans using these approaches,” explained Dr. Lanza. "We hope that these new approaches will result in the future expansion of pluripotent stem cell lines available for human therapies. However, it is important to emphasize the urgent need to have continued access to surplus IVF embryos that would otherwise be discarded.” Dr. Lanza strongly encouraged the Senators to support the Stem Cell Research Enhancement Act of 2005 (HR 810) and applauded the sponsors of this bill for their commitment to supporting embryonic stem cell research and the advancement of regenerative medicine. "While you were listening to this testimony,” Lanza explained, "another 10 Americans have died of diseases that could potentially be treated using stem cells in the future. It would be tragic not to pursue all options and methods available to us to get this technology to the bedside as soon as possible.”

"We are encouraged by the bipartisan support for the Stem Cell Research Enhancement Act of 2005 in both the House and the Senate,” said William M. Caldwell, Chief Executive Officer of ACT. "We applaud the sponsors of this bill for their leadership in moving this country forward in this promising field of regenerative medicine.”

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., a Nevada corporation, is a biotechnology company applying stem cell technology in the emerging field of regenerative medicine. The company is currently headquartered in Worcester, Massachusetts.

For more information about the company, including Dr. Lanza's testimony, visit "http://www.advancedcell.com":http://www.advancedcell.com

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for
the company and its subsidiary, Advanced Cell, Inc., and any other statements about the future
expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such
forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended March 31, 2005.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Press Contact


Chad Griffin, Noelle Gambill
(805) 252-3922

Download PDF


Lanza_testifies_before_senate_subcommittee_7_12_05.pdf

To view PDF Files, you must have Acrobat Reader.

Download Adobe Acrobat